{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55","spread":"55","upperLimit":"59","value":"57"},{"groupId":"OG001","lowerLimit":"29","spread":"29","upperLimit":"112","value":"47.5"},{"groupId":"OG002","lowerLimit":"23","spread":"23","upperLimit":"216","value":"54.0"},{"groupId":"OG003","lowerLimit":"26","spread":"26","upperLimit":"281","value":"56.0"},{"groupId":"OG004","lowerLimit":"1","spread":"1","upperLimit":"166","value":"52.0"},{"groupId":"OG005","lowerLimit":"21","spread":"21","upperLimit":"298","value":"125.0"},{"groupId":"OG006","lowerLimit":"42","spread":"42","upperLimit":"53","value":"46.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR) per RECIST v1.1 and mRECIST v1.1. by investigator determination.","dispersionType":"Full Range","groups":[{"description":"INCAGN01949 7mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG000","title":"PART 1 Dose 1 (7 mg)"},{"description":"INCAGN01949 20mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG001","title":"PART 1 Dose 2 (20 mg)"},{"description":"INCAGN01949 70mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG002","title":"PART 1 Dose 3 (70 mg)"},{"description":"INCAGN01949 200mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG003","title":"PART 1 Dose 4 (200 mg)"},{"description":"INCAGN01949 350mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG004","title":"PART 1 Dose 5 (350 mg)"},{"description":"INCAGN01949 700mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG005","title":"PART 1 Dose 6 (700 mg)"},{"description":"INCAGN01949 1400mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG006","title":"PART 1 Dose 7 (1400 mg)"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set population include all subjects enrolled in the study who received at least 1 dose of INCAGN01949.","reportingStatus":"POSTED","timeFrame":"Baseline and every 8 weeks, up to 11 months","title":"Progression-free Survival Per RECIST and Modified RECIST","type":"SECONDARY","unitOfMeasure":"Days"}